



12-26-02

1647

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 00-422)

PATENT

In re Application of: Yan et al.

Serial No.: 09/619,198

Filed: July 19, 2000

For: VGF Polypeptides and Methods  
of Treating VGF-Related Disorders

Before the Examiner: R. Hayes

Group Art Unit: 1647

RECEIVED

DEC 30 2002

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

Sir:


TRANSMITTAL LETTER

1. We are transmitting herewith the attached papers for the above-described patent application:  
Response to Office Action and return postcard.
2. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.
3. CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 C.F.R. 1.10: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in an envelope addressed to: Commissioner for Patents, Washington D.C. 20231, on December 23, 2002.

Respectfully submitted,  
McDonnell Boehnen Hulbert & Berghoff

Dated: December 23, 2002

By:

  
Donald L. Zuhn, Ph.D.  
Reg. No. 48,710



RECEIVED

DEC 30 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 00-422)

TECH CENTER 1600/2900

PATENT

#12/B  
(NE)  
DmT  
1-16-03

In re Application of: Yan et al. )

Serial No.: 09/619,198 )

Filed: July 19, 2000 )

For: VGF Polypeptides and Methods )  
of Treating VGF-Related Disorders )

Before the Examiner: R. Hayes

Group Art Unit: 1647

Commissioner for Patents  
Washington, D.C. 20231

Sir:

**RESPONSE TO OFFICE ACTION MAILED OCTOBER 21, 2002**

Responsive to the Office Action mailed October 21, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

**AMENDMENTS**

The Examiner is respectfully requested to enter the following amendments.

**In the specification:**

Please amend the paragraphs at page 6, lines 9-17 as follows:

Figure 1 illustrates the body weight of VGF knockout mice (#2, #6, #7, and #1) following administration of VGF-1a (SEQ ID NO: 2). The administration of VGF-1a was ceased at day 5 (as indicated by the arrow);

Figure 2 illustrates the antibody titer levels of a rabbit injected with VGF-1 (SEQ ID NO:1), calculated at 1:100 to 2x serial dilution; A represents samples measured at 4 weeks after initial injection, B represents samples measured at 6 weeks after initial injection, C represents samples measured at 8 weeks after initial injection, and D-H

REH 11/27/03  
Do Not  
enter